Core Insights - o9 has successfully deployed its Demand Planning and Supply Planning solutions for Teleflex Incorporated globally, marking a significant step in Teleflex's multi-year initiative to improve its integrated business planning and supply chain management capabilities [1] Company Overview - Teleflex Incorporated is recognized as a leading global provider of medical technologies, indicating its strong position within the healthcare industry [1] Technology Implementation - The implementation of o9's platform is aimed at enhancing Teleflex's end-to-end integrated business planning, which is crucial for optimizing supply chain management [1]

Group 1 - Teleflex (TFX) is currently facing challenges in early 2026, despite being recognized as a long-term value creator [1] - The company is experiencing a rough period, indicating potential difficulties in its operational or financial performance [1] Group 2 - The investment group "Value In Corporate Events" focuses on identifying opportunities related to IPOs, mergers & acquisitions, earnings reports, and corporate capital allocation [2] - The group provides coverage of 10 major events monthly, aiming to find the best investment opportunities [2]

Financial Performance and Risks - As of December 31, 2025, the company accrued $50.2 million of contingent consideration related to completed business combinations, primarily associated with Palette[125] - The company is exposed to fluctuations in foreign currency exchange rates, commodity prices, and interest rates, which may adversely affect its results[140] - Increases in commodity prices, such as plastic resin, aluminum, and steel, could increase product costs, potentially impacting the company's financial performance[141] - Recent interest rate increases have adversely affected the company's borrowing costs and may impact customers' purchasing ability[142] - Changes in tax laws and fluctuations in the effective tax rate may adversely affect the company's financial condition and results of operations[143] - As of December 31, 2025, the company had total consolidated indebtedness of $2.7 billion[156] - The company is exposed to financial risks from fluctuations in market interest rates, foreign currency exchange rates, and commodity prices, managed through a risk management program[308] - As of December 31, 2025, the company has fixed rate debt obligations totaling $1 billion with an average interest rate of 4.438% and variable rate debt obligations totaling $1.65 billion with an average interest rate of 5.161%[311] - A 1.0% change in variable interest rates would result in an annual interest expense change of $16.5 million based on outstanding debt as of December 31, 2025[311] - A hypothetical 10% change in the value of the U.S. dollar against all currencies would affect the fair value of the company's contracts by $179.5 million and $182.2 million, respectively[313] International Operations - 76% of the company's full-time employees were employed in countries outside the U.S. as of December 31, 2025[130] - For the years ended December 31, 2025, 2024, and 2023, 41%, 36%, and 35% of net revenues from continuing operations were derived from operations outside the U.S.[130] - The company is subject to various risks associated with international operations, including trade protection measures and currency restrictions[132] - The company is exposed to foreign currency risks, particularly with the Euro, Chinese Renminbi, and Mexican Peso, and uses forward exchange contracts to mitigate these risks[312] - As of December 31, 2025, the total notional amount for foreign currency forward exchange contracts was $547.3 million and for cross-currency interest rate swap contracts was $1.6 billion[313] Operational and Compliance Risks - The company faces risks related to public health epidemics, which could significantly impact its operations and financial performance[126] - The company is subject to numerous environmental protection and health and safety laws, which could lead to significant compliance costs[153] - The ongoing CEO transition poses risks that could adversely affect the company's business and financial condition[147] - The company relies on strong relationships with healthcare professionals for product development, and failure to maintain these relationships could negatively impact operations[148] - The company faces risks related to potential infringement of third-party intellectual property rights, which could lead to litigation costs[150] - Cybersecurity threats could disrupt the company's operations and adversely affect customer relationships[152] Employee and Governance Matters - 6% of the company's employees were covered by union contracts or collective bargaining arrangements as of December 31, 2025[155] - The company may not pay dividends on its common stock in the future, as this is at the discretion of the board of directors[167] - The company has provisions in its corporate governing documents that could discourage or delay mergers or acquisitions, potentially reducing the market price of its common stock[168] - The indentures governing the Senior Notes allow holders to require the company to purchase their notes in cash upon a change of control, which could increase acquisition costs and deter third-party interest[169] Shareholder Information - The company has approximately 44.2 million shares of common stock outstanding as of December 31, 2025, with 3.2 million shares available for future issuance under the 2023 Stock Incentive Plan[164] - Future impairments to the value of goodwill or intangible assets could negatively affect the company's operating results[139]

Core Insights - Teleflex Incorporated (TFX) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.93, a 1% increase year-over-year, but missed the Zacks Consensus Estimate by 48.3% [1] - The company experienced a GAAP loss per share of 8 cents compared to an EPS of 77 cents in the prior-year period [1] - Full-year 2025 adjusted EPS from continuing operations was $6.98, reflecting an 8.7% increase year-over-year, but also missed the Zacks Consensus Estimate by 50.2% [1] Revenue Performance - Fourth-quarter GAAP revenues increased by 28.7% year-over-year to $569 million, missing the Zacks Consensus Estimate by 38.6% [2] - Adjusted revenues from continuing operations for the fourth quarter were $567.3 million, up 4.3% year-over-year on an adjusted constant currency basis [2] - Full-year 2025 GAAP revenues reached $1.99 billion, a 17.2% increase year-over-year, but fell short of the Zacks Consensus Estimate by 39.7% [2][3] Segment Analysis - The Vascular segment reported pro forma adjusted revenues of $240.2 million, up 5.6% on a reported basis [4] - The Interventional business saw net revenues of $216.6 million, a significant increase of 108.7% on a reported basis [5] - The Surgical segment recorded net revenues of $110.5 million, showing a slight increase of 0.6% on a reported basis [5] Margin Analysis - Gross profit for the fourth quarter was $307.4 million, up 14.4% year-over-year, but the gross margin contracted by 678 basis points to 54% due to a 51% rise in the cost of goods sold [6][8] - Adjusted operating profit decreased by 40.8% year-over-year to $36.3 million, with the adjusted operating margin contracting by 751 basis points to 6.4% [6] Liquidity Position - Teleflex ended the fourth quarter of 2025 with cash and cash equivalents of $378.6 million, an increase from $247.8 million at the end of the fourth quarter of 2024 [9] - Net cash flow from operating activities was $96.7 million, down from $301.9 million in the previous year [9] 2026 Guidance - The company expects GAAP revenue growth for 2026 to be in the range of 14.4-15.4% [10] - Adjusted EPS for 2026 is anticipated to be between $6.25 and $6.55, while the Zacks Consensus Estimate for EPS is pegged at $15.08 [11] Overall Assessment - Teleflex's fourth-quarter results were weaker than expected, with both earnings and revenues missing estimates [12] - The Vascular segment showed growth driven by increased demand, but this was offset by a challenging prior-year comparison [12] - The Surgical business benefited from volume-based procurement in China, but margin contractions raise concerns for future performance [13]

Financial Data and Key Metrics Changes - For 2025, adjusted earnings per share (EPS) was $6.98, representing an 8.7% increase year-over-year, primarily due to higher revenue and adjusted operating income [16][17] - Adjusted gross margin for 2025 was 63.7%, a decrease of 200 basis points year-over-year, attributed to tariffs, the acquisition of Vascular Intervention, and increased logistics costs [15][16] - Adjusted operating margin for 2025 was 22.7%, reflecting a 230 basis point decrease year-over-year due to gross margin pressure and higher operating expenses [15][16] Business Line Data and Key Metrics Changes - Vascular revenue increased 2.4% year-over-year to $472.7 million, driven by growth in Central Access, hemostatic, and atomization products [14] - Interventional revenue was $427.5 million, an increase of 8.1%, supported by a broad portfolio [14] - Surgical revenue was $219.3 million, reflecting a 3.2% increase, influenced by volume-based procurement in China [14][15] Market Data and Key Metrics Changes - Continuing operations delivered 4.7% pro forma adjusted constant currency revenue growth in the second half of 2025, establishing a solid foundation for future growth [28][22] - Pro forma adjusted constant currency revenue growth for 2026 is expected to be in the range of 4.5%-5.5% [22] Company Strategy and Development Direction - The company is undergoing a transformation to optimize its portfolio and focus on high-growth areas, with plans to return significant capital to shareholders through a $1 billion share repurchase program [5][27] - The strategic divestitures of Acute Care, Interventional Urology, and OEM businesses are expected to close in the second half of 2026, with net proceeds of approximately $1.8 billion to be used for share repurchases and debt repayment [7][20] - R&D investment for RemainCo is expected to represent approximately 8% of sales, up from 5% historically, indicating a focus on product innovation [8][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit revenue growth and significant increases in adjusted EPS in 2027 and beyond, driven by cost mitigation and capital deployment actions [30][50] - The company is actively managing stranded costs of approximately $90 million associated with the divestitures, with plans to offset these through transition service agreements and restructuring initiatives [9][24] Other Important Information - The company is currently in a CEO search process, focusing on candidates with experience in high-growth, mid-size organizations operating in global healthcare settings [51] - A restructuring plan has been approved to eliminate stranded costs and streamline operations, targeting approximately $50 million in annual pre-tax savings [24][30] Q&A Session Summary Question: Use of proceeds from divestitures - The company plans to allocate $1 billion for share repurchases and approximately $800 million for debt repayment, primarily targeting the deferred draw revolver from the Bison acquisition [33] Question: Restructuring savings impact on EPS guidance - Some restructuring savings are included in the EPS guidance range of $6.25-$6.55 for 2026, with additional savings expected post-2026 [34] Question: Confidence in revenue growth for 2026 - The company is confident in its growth trajectory due to sales synergies and easier comparisons in the second half of 2026, despite some ongoing volume-based procurement impacts [81] Question: BIOTRONIK integration update - The integration of the BIOTRONIK sales force is progressing well, with no significant talent losses and opportunities for revenue synergies identified [69][70] Question: Future margin expansion post-transition service agreements - The company aims to mitigate stranded costs and leverage operational efficiencies to improve margins, with expectations for continued growth in earnings and margins beyond 2026 [75][76]

Financial Data and Key Metrics Changes - For 2025, adjusted earnings per share (EPS) was $6.98, representing an 8.7% increase year-over-year, primarily due to higher revenue and adjusted operating income, including the impact of the Vascular Intervention acquisition [16][17] - Adjusted gross margin for 2025 was 63.7%, a decrease of 200 basis points year-over-year, attributed to tariffs, the addition of the Vascular Intervention acquisition, and increased logistics costs [15][16] - Adjusted operating margin for 2025 was 22.7%, reflecting a 230 basis point decrease due to gross margin pressure and higher operating expenses [16] Business Line Data and Key Metrics Changes - Vascular revenue increased 2.4% year-over-year to $472.7 million, driven by growth in Central Access, hemostatic, and atomization products [14] - Interventional revenue was $427.5 million, an increase of 8.1%, supported by a broad Interventional portfolio [14] - Surgical revenue was $219.3 million, reflecting a 3.2% increase, impacted by volume-based procurement in China [14] Market Data and Key Metrics Changes - Continuing operations delivered 4.7% pro forma adjusted constant currency revenue growth in the second half of 2025, establishing a solid foundation for future mid-single-digit revenue growth [22][28] - Pro forma adjusted constant currency revenue growth guidance for 2026 is expected to be in the range of 4.5%-5.5% [22] Company Strategy and Development Direction - The company is undergoing a transformation to optimize its portfolio, focusing on becoming a more streamlined medical technologies leader [27] - Strategic divestitures of the Acute Care, Interventional Urology, and OEM businesses are expected to close in the second half of 2026, with net proceeds of approximately $1.8 billion to be used for share repurchases and debt reduction [7][20][30] - R&D investment for RemainCo is expected to represent approximately 8% of sales, up from about 5% historically, indicating a focus on product innovation [8][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EPS guidance for 2026 in the range of $6.25-$6.55, despite the impact of stranded costs related to divestitures [9][21] - The company anticipates significant improvements in margins and adjusted EPS in 2027 and beyond, driven by capital deployment actions and cost-saving initiatives [30][50] Other Important Information - The company is actively conducting a CEO search following the transition of leadership, focusing on candidates with experience in high-growth organizations [5][51] - A restructuring plan has been approved to mitigate approximately $50 million in stranded costs, aimed at streamlining operations and improving long-term cost structure [24][30] Q&A Session Summary Question: Use of proceeds from divestitures - The company plans to allocate $1 billion for share repurchases and approximately $800 million for debt repayment, primarily targeting the deferred draw revolver from the BIOTRONIK acquisition [33] Question: Restructuring savings impact on EPS guidance - Some restructuring savings are included in the EPS guidance for 2026, with additional savings expected post-2026 [34] Question: Confidence in revenue growth for 2026 - Confidence in revenue growth is based on anticipated sales synergies and easier comparisons in the second half of 2026, as the impact of volume-based procurement is expected to lessen [81]

An audio replay of the call will be available beginning either on the Teleflex website or by telephone. Teleflex Incorporated Year-End 2025 Earnings Conference Call 2/26/2026 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. at 11:00 am Eastern Time on February 26, 2026 Today's Speakers St ...

Core Viewpoint - Teleflex (TFX) is expected to report quarterly earnings of $3.73 per share, reflecting a year-over-year decline of 4.1%, while revenues are anticipated to reach $925.96 million, marking a 16.4% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.2% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Estimates - The consensus estimate for 'Net Revenues- Interventional' is $274.02 million, showing a significant year-over-year increase of 70.8% [5]. - 'Net Revenues- Interventional Urology' is expected to be $80.73 million, reflecting a decline of 4.9% from the previous year [5]. - 'Net Revenues- OEM' is projected at $85.31 million, indicating a slight decrease of 0.1% year-over-year [5]. - 'Net Revenues- Vascular Access' is estimated to reach $205.12 million, with an increase of 8.4% from the prior year [6]. - 'Net Revenues- Anesthesia' is expected to be $99.90 million, reflecting a 4.8% increase year-over-year [6]. - 'Net Revenues- Other' is projected at $64.41 million, indicating a 10.7% increase from the previous year [6]. - 'Net Revenues- Surgical' is estimated at $128.49 million, showing a 5.4% increase year-over-year [7]. - 'Geographic Revenues- Americas' is expected to reach $577.44 million, reflecting a 6.8% increase from the prior year [7]. - 'Geographic Revenues- EMEA' is projected at $203.23 million, indicating a significant increase of 26.2% year-over-year [7]. - 'Geographic Revenues- Asia' is estimated to be $115.99 million, reflecting a 23.9% increase from the previous year [8]. Stock Performance - Teleflex shares have returned +7.3% over the past month, outperforming the Zacks S&P 500 composite, which has seen a -0.3% change [8]. - The company holds a Zacks Rank 4 (Sell), suggesting it may underperform the overall market in the near future [8].

Core Viewpoint - Teleflex Incorporated will host a conference call on February 26, 2026, to discuss its fourth quarter 2025 financial results and provide an operational update [1] Company Information - Teleflex is a global provider of medical technologies focused on improving health and quality of life [1] - The company aims to become the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [1] - Teleflex's product brands include Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [1] Conference Call Details - The conference call is scheduled for 8:00 a.m. Eastern Time on February 26, 2026 [1] - Participants can pre-register for the call through a provided link and access it via a live audio webcast on the company's website [1] - An audio replay will be available starting at 11:00 a.m. Eastern Time on the same day, accessible through the Teleflex website or by telephone [1]

Core Viewpoint - TFX is undergoing a significant strategic adjustment announced in December 2025, which is expected to continue into 2026 [1] Group 1: Company Project Progress - TFX announced the sale of its emergency care, interventional urology, and OEM businesses for $2.03 billion, with board approval and expected completion in the second half of 2026, subject to regulatory approvals [2] - The company anticipates a post-tax net gain of approximately $1.8 billion from the transaction, which will be used to optimize its capital structure [2] Group 2: Fund Movements - In conjunction with the business sale, TFX's board approved a stock repurchase plan of up to $1 billion, primarily funded by the proceeds from the sale, aimed at enhancing shareholder returns [3] Group 3: Strategic Advancement - Following the divestiture of non-core businesses, TFX will focus more on high-growth areas such as vascular access, interventional, and surgical sectors [4] - The integration effects of the previously announced acquisition of the BodiLink vascular intervention business (approximately €760 million) will also be closely monitored, as it may impact mid- to long-term performance [4]